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MAKING ROOM FOR PATIENT AUTONOMY IN HEALTH 
INFORMATION EXCHANGE: THE ROLE OF INFORMED CONSENT 
INTRODUCTION 
Over the past fifty years, the doctrine of informed consent has played an 
important role in changing the dynamics of the doctor-patient relationship.1  In 
the past decade, health information technology (“HIT”) has played an 
increasingly important role in changing the dynamics of the health care 
industry.2  Years from now, will onlookers note that the doctrine of informed 
consent has played an important role in HIT?  This Comment examines the 
extension of informed consent from the treatment context to the context of 
health information sharing, focusing on the distinct roles of providers and 
payers therein. 
Health information sharing across industry stakeholders represents a 
growing aspect of HIT development—one positioned to bring advances in both 
clinical and non-clinical areas of the health care industry.3  This sharing, 
facilitated through health information exchange (“HIE”), will give a physician 
immediate and timely access to a patient’s health information and amplify the 
patient information to which a physician has access during a clinical encounter.  
Until recently, physicians have been restricted to patient information from 
paper or electronic medical records stored in their offices.4  Through HIE, 
 
 1. See JESSICA W. BERG ET AL., INFORMED CONSENT: LEGAL THEORY AND CLINICAL 
PRACTICE 44 (2d ed. 2001) (describing the onset of contemporary informed consent litigation in 
the mid-1950s and the consequent requirements imposed upon the physician in the physician-
patient relationship). 
 2. See DELOITTE & TOUCHE USA LLP, HEALTH INFORMATION EXCHANGE (HIE) 
BUSINESS MODELS: THE PATH TO SUSTAINABLE FINANCIAL SUCCESS 4 (2006), available at 
http://www.providersedge.com/ehdocs/ehr_articles/Health_Info_Exchange_Business_Models.pdf
 (noting that although HIE has its origin in the early 1990s, notable developments commenced 
with health information sharing within communities at the start of the twenty-first century); 
Joshua R. Vest & Larry D. Gamm, Health Information Exchange: Persistent Challenges and New 
Strategies, 17 J. AM. MED. INFORMATICS ASS’N 288, 289 (2010) (describing efforts to exchange 
health information electronically from the early 1990s to present). 
 3. See generally Leslie Pickering Francis, The Physician-Patient Relationship and a 
National Health Information Network, 38 J.L. MED. & ETHICS 36 (2010) (describing clinical 
benefits such as automatic data entry, reduced error risks, reduced costs, and increased 
transparency in physician-patient relationships, with non-clinical benefits including improved 
external evaluation of physician performance, quality improvement, and expanded research). 
 4. OFFICE OF THE NAT’L COORDINATOR FOR HEALTH INFO. TECH., GET THE FACTS 
ABOUT ELECTRONIC HEALTH RECORDS: ADVANCING AMERICA’S HEALTH CARE (2011), 
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physicians will treat their patients based upon a more complete patient health 
record that combines information such as recent lab tests, diagnoses, and 
medical history recorded by other treating physicians as well.  This electronic 
health record (“EHR”) is marked by its interoperability; that is, an EHR is 
“created, managed, and consulted by authorized clinicians and staff across 
more than one health care organization.”5  Thus a primary care physician, 
dermatologist, cardiologist, and maybe even dentist are able to upload directly 
to their common patient’s EHR and then treat the patient based upon this more 
complete patient health picture.  Among potential benefits of HIE, patients 
become drivers of HIT.  Among potential risks, patients are left in the 
backseats listening to loud music. 
If patients are to be autonomous stakeholders in HIE, this Comment argues 
that informed consent must have an integral role in HIE development and 
implementation.  Part I describes the HIE framework, stakeholders, and patient 
consent models on the table.  Part II introduces informed consent as one means 
with which to safeguard patient autonomy as the health care industry moves 
into the future.  Applying this doctrine, part III proposes that patient autonomy 
is best reflected in a consent model that calls for affirmative patient 
participation when providers will exchange EHRs.  Finally, part IV examines 
the implications of participation in HIE by those outside of the treatment 
context, and specifically by third-party payers (“payers”), ultimately proposing 
that a role for payers necessarily entails a special role for informed consent. 
I.  BIG PICTURE 
HIT has assumed a leading role in the future of health care in the United 
States.  Even cautious accounts recognize the vast benefits promised by a 
technologically-integrated health care system.6  To name a few, the 
implementation of HIE is projected to improve quality of care, reduce health 
care costs, and expand medical research.7  Indeed, HIT development has been 
 
available at http://healthit.hhs.gov/portal/server.pt/gateway/PTARGS_0_0_7461_2996_20385_ 
43/http;/wci-pubcontent/publish/onc/common_content/alt_spot_light/files/hitech_overview_con 
sumer_fact_sheet_v5.pdf. 
 5. THE NAT’L ALLIANCE FOR HEALTH INFO. TECH., REPORT TO THE OFFICE OF THE 
NATIONAL COORDINATOR FOR HEALTH INFORMATION TECHNOLOGY ON DEFINING KEY 
HEALTH INFORMATION TECHNOLOGY TERMS 15 (2008) [hereinafter NATIONAL ALLIANCE]. 
 6. See Richard J. Baron et al., Electronic Health Records: Just around the Corner?  Or 
over the Cliff?, 143 ANNALS INTERNAL MED. 222, 223–24 (2005) (describing multiple benefits of 
EHR use, but also describing first-hand the financial and practical difficulties of implementing 
EHR use in a primary care practice). 
 7. DELOITTE & TOUCHE USA LLP, supra note 2, at 7; MELISSA M. GOLDSTEIN, 
CONSUMER CONSENT OPTIONS FOR ELECTRONIC HEALTH INFORMATION EXCHANGE: POLICY 
CONSIDERATIONS AND ANALYSIS 57 (2010), available at healthit.hhs.gov/portal/server.pt/ 
gateway/PTARGS_0_11673_911197_0_0_18/ChoiceModelFinal032610.pdf. 
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identified as not only beneficial, but indispensable: “[t]he fragmentation of 
health care delivery without the parallel distribution of critical health care 
information lays the groundwork for an error-prone and inefficient health care 
delivery system.”8  Developing an integrated system has been a major focus of 
health reform in the United States.9  In 2004, former President George W. 
Bush created the Office of the National Coordinator for Health Information 
Technology (“ONC”), predicting that Americans would have interoperable 
EHRs by 2014.10  As part of the American Recovery and Reinvestment Act 
(“ARRA”) of 2009, President Obama directed approximately twenty billion 
dollars to the Health Information Technology (“HITECH”) Act, which 
mandates the ONC to adopt HIT standards and create incentives for the 
adoption of EHR technology.11 
This section briefly addresses the HIE framework.  It describes the steps 
being taken to realize the revolutionary potential of HIT, the stakeholders 
involved in HIE, and HIE patient consent models currently under consideration 
and/or use.  Yet “[t]hat confidence does not conflict with caution,” reminds 
Epictetus.12  The implementation of HIE has potentially negative ramifications, 
not the least of which being its effect on patients’ control of personal health 
information.13  Accordingly, this section presents the HIE framework as a 
foundation for considering the integral role of informed consent therein. 
A. HIE Framework 
HIE is a process,14 defined by the Department of Health and Human 
Services (“HHS”) as “[t]he electronic movement of health-related information 
among organizations according to nationally recognized standards.”15  To 
present, there are 234 public or private HIE initiatives working on intrastate 
 
 8. Gregory W. Daniel et al., Efficiency and Economic Benefits of a Payer-Based Electronic 
Health Record in an Emergency Department, 17 ACAD. EMERGENCY MED. 824, 824 (2010). 
 9. Vest & Gamm, supra note 2, at 288–89. 
 10. Mike Allen, Bush Touts Plan for Electronic Medicine: Campaign Aimed at ‘Wired’ 
Voters, WASH. POST, May 28, 2004, at A8; About ONC, OFF. NAT’L COORDINATOR FOR HEALTH 
INFO. TECH., http://healthit.hhs.gov/portal/server.pt/community/healthit_hhs_gov__onc/1200 (last 
visited Mar. 15, 2012). 
 11. Daniel J. Gilman & James C. Cooper, There Is a Time to Keep Silent and a Time to 
Speak, the Hard Part Is Knowing Which Is Which: Striking the Balance Between Privacy 
Protection and the Flow of Health Care Information, 16 MICH. TELECOMM. & TECH. L. REV. 
279, 280 nn.2 & 4 (2010). 
 12. EPICTETUS, THE DISCOURSES AS REPORTED BY ARRIAN, THE MANUAL, AND 
FRAGMENTS bk. II, at 213 (E. Capps et al. eds., W. A. Oldfather trans., Loeb Classical Library 
1926) (c. 108 A.D.). 
 13. Deborah C. Peel, Op-Ed., Your Medical Records Aren’t Secure, WALL ST. J., Mar. 24, 
2010, at A17. 
 14. NATIONAL ALLIANCE, supra note 5, at 23. 
 15. Id. 
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and interstate levels to achieve interoperability in the exchange of health 
information.16  Seventy-three initiatives are now operational; that is, they 
transmit data used by healthcare stakeholders.17  By far, the majority of HIE 
initiatives are being driven by statewide leadership—whether in planning or 
implementation phases.18  Collaborative efforts on the intrastate and interstate 
levels have been implemented in the form of Regional Health Information 
Organizations (“RHIOs”).19  Where health information organizations (“HIOs”) 
organize and oversee the exchange of health information, RHIOs do so within 
defined geographic regions in order to improve the health of the populations 
therein.20 
As advancements in HIE continue on intrastate and interstate levels, the 
ultimate goal remains to transition HIE initiatives into a Nationwide Health 
Information Network (“NHIN”).21  Through the NHIN Exchange, federal and 
private initiatives are working to establish nationwide standards, services, and 
policies to facilitate the exchange of information on a national level.22  To this 
end, the ONC Health IT Policy Committee is making recommendations 
regarding the achievement of secure and viable HIE on a national scale.23 
B. Stakeholders in HIE 
The success of HIE requires a host of stakeholders.  Providers, ranging 
from physicians, physician assistants, nurses, hospitals, clinics, outpatient 
centers, and many more, create the front line of patient care.  Currently, 
hospitals and primary care physicians are the largest stakeholders, among both 
 
 16. EHEALTH INITIATIVE, THE STATE OF HEALTH INFORMATION EXCHANGE IN 2010: 
CONNECTING THE NATION TO ACHIEVE MEANINGFUL USE 5, 30 (2010), available at 
http://www.thcc2.org/PDFs/ehealth_meaningfull_use.pdf. 
 17. Id. at 8 (noting that this number is up from nine in 2004, thirty-two in 2007, and fifty-
seven in 2009). 
 18. Id. at 16 (showing that of 133 responding initiatives, 107 initiatives are working with at 
least “formal state leadership” as compared to twenty-six operating on more local levels). 
 19. DELOITTE & TOUCHE USA LLP, supra note 2, at 4; Vest & Gamm, supra note 2, at 290. 
 20. NATIONAL ALLIANCE, supra note 5, at 25. 
 21. See OFFICE OF THE NAT’L COORDINATOR FOR HEALTH INFO. TECH., GET THE FACTS 
ABOUT THE NATIONWIDE HEALTH INFORMATION NETWORK, DIRECT PROJECT, AND CONNECT 
SOFTWARE (2010), available at http://healthit.hhs.gov/portal/server.pt/gateway/PTARGS_0_ 
12811_953714_0_0_18/HITECH_FS_HIN_Facts_V1.pdf (discussing efforts to expand HIE 
through NHIN standards). 
 22. Id. 
 23. For access to the Committee’s recommendations through Dec. 7, 2011, see National IT 
Policy Committee: Recommendations to the National Coordinator for Health IT, OFF. NAT’L 
COORDINATOR FOR HEALTH INFO. TECH., http://healthit.hhs.gov/portal/server.pt?open=512& 
objID=1815&parentname=CommunityPage&parentid=7&mode=2&in_hi_userid=11113&cached
=true (last visited Feb. 1, 2012). 
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providers and HIE stakeholders generally.24  The federal government, through 
the Veterans Health Administration, is the largest provider in the United 
States.25  HIE vendors are also necessary participants.  Vendors put the 
“Exchange” in “Health Information Exchange,” providing the technology to 
replace paper and non-interoperable electronic medical records with 
interoperable EHR databases.26  A recent study has identified five vendors as 
market dominators—out of thirty-eight potential vendors, the only five to be 
considered by more than ten percent of buyers.27  Patients are the very source 
of health information.  Having one’s health information entered into an 
exchange means better communication between treating physicians, but it also 
allows for the aggregation of health information into databases that will 
become invaluable to providers, researchers, public health analysts, payers, and 
beyond.28  Finally, federal and state agencies have been very instrumental in 
the early stages of HIE development.29  Federal ARRA funding has been 
crucial to HIE start-up, although in 2010, 107 of 199 responding HIE 
initiatives reported no dependence upon federal funding for sustainability.30  
As ARRA funds continue to diminish, it will be crucial for all initiatives to rely 
upon alternate funding.31  Aside from funding, government agencies will have 
a continuing role in standard-setting and the development of HIE across states 
and ultimately on a national level.32  Stakeholders who operate outside of the 
treatment context, including payers, researchers, and public health analysts, are 
addressed in part IV. 
 
 24. EHEALTH INITIATIVE, supra note 16, at 15. 
 25. About VHA, DEP’T VETERANS AFF., http://www.va.gov/health/aboutVHA.asp (last 
updated Oct. 5, 2011).  See generally Colene M. Byrne et al., The Value from Investments in 
Health Information Technology at the U.S. Department of Veterans Affairs, 29 HEALTH AFF. 629 
(2010) (providing a detailed update on the status of HIT developments in the Department of 
Veterans Affairs). 
 26. The current meaningful use capability requirements for vendors’ EHR systems are set 
out in 45 C.F.R. §§ 170.205–.306.  For a vendor comparison tool, see Margaret Steen, 17 Leading 
EHR Vendors, INFO. WEEK: HEALTHCARE (Dec. 18, 2010), http://www.informationweek.com/ 
news/galleries/healthcare/EMR/228800771. 
 27. Anthony Guerra, Five Vendors Dominate HIE Market, INFO. WEEK: HEALTHCARE (July 
8, 2010), http://www.informationweek.com/news/healthcare/clinical systems/showArticle.jhtml? 
articleID=225702631 (reporting on KLAS, HEALTH INFORMATION EXCHANGES: PERCEPTION IN 
AN EXPANDING FRONTIER (2010)). 
 28. See generally Francis, supra note 3 (describing in detail the clinical and non-clinical 
benefits of EHRs). 
 29. See supra notes 18–20 and accompanying text. 
 30. EHEALTH INITIATIVE, supra note 16, at 11.  The number of HIE initiatives no longer 
reliant upon federal funding has increased from 2009, when only seventy-one reported not being 
dependent.  Id. at 2. 
 31. DELOITTE & TOUCHE USA LLP, supra note 2, at 9. 
 32. EHEALTH INITIATIVE, supra note 16, at 2 (noting that HIE initiatives cite federal policy 
and governance as a major challenge). 
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Notwithstanding the importance of providers, vendors, and patients to HIE, 
consideration of each highlights important barriers to a truly integrated health 
care system.  Providers face substantial up-front financial and administrative 
burdens in the decision to invest in a system of EHRs.33  The technology 
required to support the envisioned HIE is vast, and it remains unclear whether 
vendors’ technological capacities will be able to keep up with policy.34  An 
optimal HIE database will include EHRs compiled from all patients, but 
patients may not wish to participate.35  Finally, state and federal agencies face 
significant challenges in setting standards for HIE on intrastate, interstate, and 
federal levels, garnering the trust of participants, and maintaining a balance 
between the benefits to be reaped from HIE and the risks inherent to an ever-
increasing aggregation of EHRs. 
C. Patient Consent Models 
“The issue of whether, to what extent, and how individuals should have the 
ability to exercise control over their health information represents one of the 
foremost policy challenges related to the electronic exchange of health 
information.”36  There are currently five models for patient participation in 
HIE either under consideration or in use among HIE initiatives, providing 
patients with varying levels of participation choice.37  In a “No Consent” 
model, patient health information is automatically exchanged and patients do 
not have the option to forgo participation.38  This model comports with the 
federal floor for privacy protection established by HIPAA but does not 
accommodate individual choice.39  Some states that began exchanging health 
information without first obtaining consent have, as the exchanges developed, 
adopted models incorporating choice.40  A global “Opt-Out” participation 
model maintains inclusion of a pre-defined set of health information as the 
 
 33. Gilman & Cooper, supra note 11, at 295. 
 34. Neil Versel, Privacy, Security ‘Tiger Team’ Told Granular Consent Technology is 
Flawed, FIERCEHEALTHIT (Aug. 9, 2010), http://www.fiercehealthit.com/story/privacy-security-
tiger-team-told-granular-consent-technology-flawed/2010-08-09. 
 35. Micky Tripathi et al., Engaging Patients for Health Information Exchange, 28 HEALTH 
AFF. 435, 435 (2009). 
 36. GOLDSTEIN, supra note 7, at ES-1. 
 37. Id. at 5–7. 
 38. Id. at 5.  For example, state laws in Indiana, Virginia, and Tennessee do not require 
patient consent for EHR creation.  Id. at 15. 
 39. Id. at 5–6. 
 40. Kathleen Delaney Greenbaum et al., Health Information Security and Privacy 
Collaboration, Intrastate and Interstate Consent Policy Options—Final Report 2-2 (Mar. 31, 
2009) (unpublished report prepared for the Office of the National Coordinator for Health 
Information Technology), available at healthit.hhs.gov/portal/server.pt/gateway/PTARGS_0_ 
10741_872327_0_0_18/C2_1_1_Final_Rpt.pdf. 
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exchange default, but also allows the patient to fully opt-out of participation.41  
This model has been widely adopted and is considered to be both easiest and 
most adept for creating a robust pool of EHRs while still giving patients the 
choice of whether to participate.42  Less pursued has been the global “Opt-In” 
model,43 whereby patients must actively manifest their consent to participation 
before the pre-defined set of information is entered into the exchange.44  While 
this model calls for a higher degree of patient initiative before information is 
exchanged,45 it also carries the risk of low participation levels and thus could 
vitiate the benefits of an exchange.46  The fourth and fifth consent models 
replace the global consent approach with granular participation choices: the 
“Opt-Out with Exceptions” approach has the participation default of the opt-
out model but allows patients to granularly withhold information from the 
exchange, and the “Opt-In with Restrictions” model provides a basis for a 
patients to consent to the inclusion of some, but not necessarily all, of their 
health information into the exchange.47 
Granular approaches under consideration provide patients the choice 
whether to participate in exchange based upon (1) data type; (2) provider; (3) 
time range; or (4) purpose, or some combination therein.48  Granularity by data 
type allows a patient to withhold a specific data set from the exchange.49  The 
data blocked could range from a patient’s reproductive health records, to all 
medication records, to mental health records.50  Exchange models that have 
adopted this type of granularity have done so largely based upon what they 
classify as “sensitive health information,” which is then as a data set 
 
 41. GOLDSTEIN, supra note 7, at 6.  For example, the Delaware HIE uses an opt-out consent 
mechanism for provider access (but requires no consent for EHR creation), and Maryland, 
Kentucky, and Nebraska all use an opt-out approach.  Id. at A-1, A-3; MO. OFFICE OF HEALTH 
INFO. TECH., HEALTH INFORMATION EXCHANGE OPERATIONAL PLAN L–1 (June 30, 2010), 
available at http://www.dss.mo.gov/hie/action/pdf2010/operationalplan_draft.pdf. 
 42. See Howard Anderson, Survey: ‘Opt-In’ for HIE Consent is Rare, HEALTHCARE INFO. 
SECURITY (July 23, 2010), http://www.healthcareinfosecurity.com/articles.php?art_id=2779 
(explaining that an “Opt-In” model would create an administrative burden by requiring every 
patient to sign a consent form). 
 43. See EHEALTH INITIATIVE, supra note 16, at 24 (finding that of 199 responding HIE 
initiatives, only 36 reported using an “opt-in” model to include patient information in HIE). 
 44. GOLDSTEIN, supra note 7, at 7.  States taking an opt-in approach include Massachusetts, 
New York, Rhode Island, and Washington.  Id. at A-4 to -7. 
 45. Id. at 51. 
 46. See Anderson, supra note 42. 
 47. GOLDSTEIN, supra note 7, at 6–7. 
 48. Id. at 7–12. 
 49. Id. at 8. 
 50. Id. 
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summarily withheld.51  The National Center for Vital and Health Statistics 
(“NCVHS”) has recommended that the future NHIN adopt a consent model 
that allows a patient to control the disclosure of nationally predetermined 
“sensitive” categories of health information.52  Sequestered information would 
be marked by a notation in the patient’s record indicating that certain 
information has been blocked from access.53  Where an exchange adopts a 
model with granularity by provider, the patient may have the choice to disclose 
her EHR to either specific providers (Dr. Jones and Dr. Smith only) or to 
specific provider types (all MDs but no RNs), or to restrict access within the 
provider type (OB/GYN but not dentist).54  While this type of granularity 
threatens efficient and effective coordination of care across providers,55 it may 
serve as an effective model for patients wishing to restrict access by non-
providers (e.g. payers or researchers).56  Granularity by time range gives a 
patient control of information according to its time and date.57  Among uses for 
such a model is emergency room treatment, in which emergency providers 
could “break the glass” of the protected information and access it only for the 
time period in which the patient is treated for her emergency.58  Finally, where 
a patient has granular control according to purpose of access, she may choose 
the ways in which her EHR will be put to use (e.g. for clinical purposes but not 
for research).59 
There is notable confusion for a HIE initiative regarding the degree of 
consent required within each state, the consent requirements for a multi-state 
approach, and the best approach in anticipation of the developing NHIN.  The 
HIPAA Privacy Rule does not require patient consent for covered entities 
(including providers and payers) to use identifiable health information for 
 
 51. Id. at 9.  For example, federal law affords extra protection to drug and substance abuse 
information.  42 C.F.R. § 2.31(a)(1) (2010). 
 52. Letter from Simon P. Cohn, Chairman, Nat’l Comm. on Vital and Health Statistics, to 
Michael O. Leavitt, Sec’y, Dep’t of Health and Human Servs., Individual Control of Sensitive 
Health Information Accessible via the Nationwide Health Information Network for Purposes of 
Treatment 3–4 (Feb. 20, 2008), available at www.ncvhs.hhs.gov/080220lt.pdf [hereinafter Letter 
from Simon P. Cohn]. 
 53. Id. at 7. 
 54. GOLDSTEIN, supra note 7, at 9. 
 55. See id. (noting that granularity by provider could compromise coordination of care 
because a physician may not be able to get “the full picture” of the patient); Letter from Simon P. 
Cohn, supra note 52, at 5–6 (explaining that granularity by provider may burden the efficiency by 
creating the need to question patients about every category to insure no relevant information is 
missing). 
 56. See infra Part IV for consideration of granularity to the exchange in which payers 
participate. 
 57. GOLDSTEIN, supra note 7, at 10. 
 58. Id.; MO. OFFICE OF HEALTH INFO. TECH., supra note 41, at 46. 
 59. GOLDSTEIN, supra note 7, at 10. 
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clinical, payment, or health care operations purposes.60  It does, however, 
allow states to require consent for these purposes, and some states have done 
so through statutes and/or case law.61  The Health Information Security and 
Privacy Collaboration (“HISPC”), a national initiative developed by contract 
with HHS, has been instrumental in addressing privacy and security challenges 
inherent in multi-state collaborative approaches to HIE.62  HISPC conducted a 
study of statutory options with which an interstate (and eventually national) 
exchange could implement uniform consent procedures.63  Comparing 
statutory provisions of model act, choice of law, uniform code, and interstate 
compact, the study ultimately recommended that an interstate compact would 
best resolve conflicts among states, legally bind participating states, and 
quickly adjust to fit ever-growing exchange.64  An outstanding issue is 
whether—in light of the constitutional requirement that states enter into 
contracts with each other only after obtaining the consent of Congress—an 
interstate compact would require congressional approval.65 
The ONC Health IT Committee’s Privacy and Security Tiger Team has 
grappled with the appropriate role of patient consent in exchanging health 
information.  In August 2010 it released its recommendation that patients have 
the opportunity to consent to participation before any personal health 
information is exchanged with a third party, i.e. beyond the direct treatment 
context.66  Notwithstanding the Tiger Team’s recommendation, however, some 
highly successful HIE initiatives do exchange certain personal health 
information without first obtaining consent.67 In the wake of potentially 
nationalized exchange, the viability of such a no-consent framework is 
 
 60. Greenbaum et al., supra note 40, at 2-1. 
 61. GOLDSTEIN, supra note 7, at 48; Greenbaum et al., supra note 40, at 2-1. 
 62. The Health Information Privacy and Security Collaboration, OFF. NAT’L COORDINATOR 
FOR HEALTH INFO. TECH., http://healthit.hhs.gov/portal/server.pt?open=512&mode=2&cached 
=true&objID=1240 (last updated April 9, 2010). 
 63. Greenbaum et al., supra note 40, at 1-1 to -2. 
 64. Id. at 5-6 to -7. 
 65. Id. at 5-7 to -8. 
 66. Letter from Paul Tang, Vice Chair, HIT Policy Comm., to David Blumenthal, Nat’l 
Coordinator for Health Info. Tech., Dep’t of Health and Human Services 10 (Sept. 1, 2010), 
available at http://healthit.hhs.gov/portal/server.pt/gateway/PTARGS_0_11673_949147_0_0_18/ 
Transmit-Priv-SecTigerTeam-Nov-19-10.pdf [hereinafter Letter from Paul Tang] (“When the 
decision to disclose or exchange the patient’s identifiable health information from the provider’s 
record is not in the control of the provider or that provider’s organized health care arrangement 
(‘OHCA’), patients should be able to exercise meaningful consent to their participation.”) 
(emphasis in original). 
 67. For example, the Indiana HIE takes a “no consent” approach, but has established trust 
through enhanced privacy protections such as withholding behavioral and mental health 
information from exchange.  Lisa A. Eramo, Permission Predicament, FOR THE REC., Sept. 13, 
2010, at 24. 
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questionable; as exchanges grow and consolidate geographically, more 
stakeholders will necessarily become involved and consequently, there will be 
increased hands in the exchange and more opportunities for threats to security 
and privacy.68  Beyond increased risks, the no consent model is troublesome as 
it fails to recognize the fundamental, per se importance of patient autonomy 
and accordingly, the role of patients as equal partners in HIE. 
In order to underscore why the implementation of particular consent 
models is so important, Part II considers the theory of informed consent and 
examines the relationship between the patient and the option of consent in HIE. 
II.  INFORMED CONSENT—THEORETICAL FRAMEWORK 
A. History and Purpose of Informed Consent 
Informed consent, as a concept, evades uniform definition.  In the health 
care context, descriptions include “process of communication,”69 “written 
permission,”70 and “the giving of information to the patient as to just what 
would be done and as to its consequences,”71 and as described below, it is 
approached from both moral and legal perspectives.  Considering the purpose 
of informed consent—and what it really means to give informed consent—is 
helpful in determining just what role informed consent should have in the 
electronic exchange of patients’ health information.  This section considers 
informed consent primarily in terms of individual autonomy.  It lays out a 
framework with which to consider informed consent in health care and 
specifically, the autonomous patient and the creation and use of EHRs. 
Professors Faden and Beauchamp describe two distinct but corresponding 
doctrines of informed consent: 1) a moral doctrine structured by principles and 
2) a legal doctrine focused on procedural rules and requirements.72  Faden and 
Beauchamp devote a great deal of attention to informed consent, from a moral 
perspective, as “autonomous authorization by a patient or subject.”73  
 
 68. Nicholas P. Terry & Leslie P. Francis, Ensuring the Privacy and Confidentiality of 
Electronic Health Records, 2 U. ILL. L. REV. 681, 725 (2007) (“[A] national, fully interoperable 
architecture poses the greatest privacy, confidentiality, and security risks and suggests that the 
protection of personal health information will depend on patient choice and legal protections.”). 
 69. Patient Physician Relationships Topics: Informed Consent, AM. MED. ASS’N, 
http://www.ama-assn.org/ama/pub/physician-resources/legal-topics/patient-physician-relation 
ship-topics/informed-consent.shtml (last visited Mar. 15, 2012). 
 70. OFFICE FOR CIVIL RIGHTS, SUMMARY OF THE HIPAA PRIVACY RULE 5 (2003), 
available at http://www.hhs.gov/ocr/privacy/hipaa/understanding/summary/privacysummary.pdf. 
 71. RUTH R. FADEN & TOM L. BEAUCHAMP, A HISTORY AND THEORY OF INFORMED 
CONSENT 275 (1986) (quoting Planned Parenthood of Cent. Mo. v. Danforth, 428 U.S. 52, 67 n.8 
(1976)). 
 72. Id. at 24–25. 
 73. Id. at 3. 
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Alternatively, the legal doctrine of informed consent is focused less on patient 
autonomy and more on a physician’s duties and liabilities—the duty to inform 
and to obtain consent before treating along with the legal mechanisms by 
which a physician avoids liability.74  The moral and legal doctrines of informed 
consent correspond, with the moral providing a foundation for the creation and 
promulgation of legal requirements.75  This Comment will argue that the 
strongest justification for informed consent in the context of HIT is necessarily 
a moral justification; patient autonomy, but not rules and requirements, justify 
upholding patient choice despite increased costs, administrative burdens, and 
even relaxed security or privacy concerns. 
The concept of autonomy has a vibrant history beginning well before 
1957—the date cited as the birth of autonomy-based informed consent in the 
United States76—and extending well beyond the bounds of the bioethical 
considerations in which the concept is so often framed:77 
[Enlightenment] philosophy reinforced emphasis on the sanctity of the 
individual conscience, which was central to beliefs of the Puritans and other 
radical Protestant groups who came to the New World from Europe . . . 
[I]ndividualistic values were reinforced by the ‘frontier mentality’ of self-
reliance that emerged with the settlement of the new continent, that remains 
highly prized in American culture today, and that further reinforces 
individualistic values.78 
Thus underlying the concept of autonomy across fields from moral philosophy 
to politics to bioethics are notions of liberty, self-rule, and individualism.79  In 
bioethics, this translates as a patient’s responsibility and control over a 
treatment plan in the face of an expert physician’s divergent but beneficent 
opinion.80 
 
 74. Id. 
 75. Id. at 24. 
 76. FADEN & BEAUCHAMP, supra note 71, at 59 (describing the views of leading authorities 
Martin Pernick and Jay Katz). 
 77. Autonomy holds a central role in Kant’s moral philosophy, namely his “categorical 
imperative” that one should “[a]ct only on that maxim by which you can at the same time will 
that it should become a universal law.” IMMANUEL KANT, GROUNDWORK FOR THE 
METAPHYSICS OF MORALS ¶ 25 (Thomas E. Hill and Arnulf Zweig eds., Arnulf Zweig trans., 
Oxford Univ. Press 2002).  This famous tenet exemplifies Kant’s reverence for rationality, 
manifested in the autonomous will—the categorical imperative is the foundational principle 
according to which the truly autonomous will conforms.  Id.  As explained by John Stuart Mill, 
“[e]ach is the proper guardian of his own health, whether bodily or mental and spiritual.”  BERG 
ET AL., supra note 1, at 23 (quoting JOHN STUART MILL, ON LIBERTY 12 (Elizabeth Rapaport ed. 
1978)). 
 78. BERG ET AL., supra note 1, at 21. 
 79. GERALD DWORKIN, THE THEORY AND PRACTICE OF AUTONOMY 6 (1991). 
 80. BERG ET AL., supra note 1, at 18–19; DWORKIN, supra note 79, at 112–13. 
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B. Autonomy Defended and Privacy Distinguished 
As legal scholar Melissa Goldstein describes the role of autonomy in HIT, 
“[i]t is this idea—that policies governing rule-based consent should be based 
on autonomous decision making—that must remain central to our policy 
making during this nascent stage of HIT development if we are to create a 
framework for health care information sharing that facilitates patient choice.”81  
This postulation presupposes that health information sharing should facilitate 
patient choice.  Legal scholar Carl Schneider points out, however, that due to 
complexities inherent in the medical context, choice may not actually be a 
keystone to patient satisfaction.82  Schneider characterizes the focus on patient 
autonomy as an “autonomy paradigm” in which “hyper-rationalist 
assumptions” lead decisionmakers to overlook the reality of patients’ fears,83 
lack of knowledge,84 and pain85 and categorize all patients as “autonomy-
maximizers.”86  “The paradigm calls for patients to make medical decisions.  
The evidence suggests that some significant number of patients are loath to 
assume that authority.”87  A response to the recent emphasis on patient 
autonomy, Schneider’s approach contends that pushing patients as 
decisionmakers may run contrary to the reality of patients’ desires: “many 
patients reject the full burden of decision autonomists would wish upon 
them.”88  However, in the context of HIT and consent to having one’s health 
information exchanged, the autonomy principle may not be so “hyper-
rational.”  Arguably, the factors that allegedly overwhelm patients in the 
treatment context will factor less strongly in decision making regarding 
participation in HIE.  Schneider points out that desire for autonomy is 
inversely correlated to the seriousness of the condition.89  Following this line 
of reasoning, it seems that when participation in HIE rather than treatment—
whether minor or serious—is at issue, there will be more room for the 
autonomous patient. 
Shifting the focus to the HIT context, it is important to distinguish 
informed consent from privacy and security.  While informed consent has an 
important role in protecting patient privacy, its function is not so restricted.90  
 
 81. Melissa M. Goldstein, Health Information Technology and the Idea of Informed 
Consent, 38 J.L. MED. & ETHICS 27, 29 (2010). 
 82. CARL E. SCHNEIDER, THE PRACTICE OF AUTONOMY: PATIENTS, DOCTORS, AND 
MEDICAL DECISIONS 32–33 (1998). 
 83. Id. at 35, 56. 
 84. Id. at 50. 
 85. Id. at 75. 
 86. Id. at 35. 
 87. SCHNEIDER, supra note 82, at 47. 
 88. Id. at xii. 
 89. Id. at 36. 
 90. Goldstein, supra note 81, at 30. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2012] MAKING ROOM FOR PATIENT AUTONOMY 897 
As described above, informed consent serves an independent purpose in 
reflecting and facilitating the patient’s independence and self-decision;91 that 
is, the patient’s ability to provide “autonomous authorization.”92  Much of the 
discussion surrounding patient HIE consent models has focused on the ways in 
which increased patient control relates to the privacy, security, and 
confidentiality risks of storing and exchanging aggregated EHRs.  The Center 
for Democracy and Technology, for example, frames the issue of consent in 
terms of its relation to privacy protection: “Patient consent should be viewed as 
one element of a comprehensive framework of privacy protections for personal 
health information, and any requirement for patient consent or authorization 
should be an adjunct to clear rules that limit how the information can be 
accessed, used and disclosed and that are adequately enforced.”93  There is no 
doubt that consent alone cannot ensure patient privacy,94 but it is misleading to 
address consent only insofar as it furthers this end.  An example borrowed 
from the context of human subjects research, the Institute of Medicine 
(“IOM”) recently recommended relieving information-based research on 
human subjects from compliance with the Common Rule,95 which requires 
informed consent.96  As Professor Mark Rothstein pointed out, however, the 
IOM’s justifications for this recommendation—including the allegedly 
minimal privacy risks involved—overlook the role of informed consent outside 
of privacy protection: “The IOM Report’s central proposal demonstrates a lack 
of respect for individuals as autonomous agents and assumes that all 
individuals have the same values and interests with regard to research.”97 
C. Theory of Informed Consent in the HIT/HIE Context 
One might argue that because the choice whether to participate in HIE 
does not entail complex treatment decisions, the choice does not need to be 
 
 91. For further discussion of the relation between autonomy and informed consent, see 
DWORKIN, supra note 79, at 100–03. 
 92. See Goldstein, supra note 81, at 27–30 (discussing Faden and Beauchamp’s formulation 
of informed consent as, in one sense, “autonomous authorization” and distinguishing informed 
consent from privacy and security protection); supra notes 72–75 and accompanying text. 
 93. CTR. FOR DEMOCRACY & TECH., RETHINKING THE ROLE OF CONSENT IN PROTECTING 
HEALTH INFORMATION TECHNOLOGY 10–11 (2009), available at http://www.cdt.org/health 
privacy/20090126Consent.pdf. 
 94. See Deven McGraw et al., Privacy as an Enabler, Not an Impediment: Building Trust 
into Health Information Exchange, 28 HEALTH AFF. 416, 418 (2009) (explaining that a heavy 
focus on the role of consent in privacy protection may serve to weaken patient privacy). 
 95. 45 C.F.R. § 46 (2010). 
 96. INST. OF MED., BEYOND THE HIPAA PRIVACY RULE: ENHANCING PRIVACY, 
IMPROVING HEALTH THROUGH RESEARCH 30–34 (2009). 
 97. Mark A. Rothstein, Currents in Contemporary Ethics: Improve Privacy in Research by 
Eliminating Informed Consent? IOM Report Misses the Mark, 37 J.L. MED. & ETHICS 507, 509 
(2009). 
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aggressively protected; that is, consent to participate in HIE is distinguished 
from consent to treatment not only in the type of choice at issue, but in what is 
at stake.  In one sense, participation in HIE does not bring to mind the 
immediate questions of bodily rights, integrity, and personal health that are 
implicit in treatment decisions.  However, in an important sense physical 
integrity is very much related to the decision whether to participate in HIE: the 
choice of whether to participate is a choice whether to grant access to personal 
health information.  EHRs are an area in which patients may feel empowered 
to make informed choices and accordingly, the choice may be that much more 
important—as Schneider argues, competent patients forgo decision making 
because the decisions are too complex.98 
HIT highlights the relationship between consent and privacy and the 
foundational importance of patient autonomy therein.  Professors Nicholas 
Terry and Leslie Francis describe an “instrumental approach” similar to Faden 
and Beauchamp’s legal doctrine of informed consent, whereby “institutions 
and compliance” rather than patient control and choice are placed at the 
forefront of privacy concerns.99  HIE presents a pivotal context for the future 
of autonomy.  Healthcare technology, itself “process-driven,” runs the risk of 
undermining an autonomy justification, but as Terry and Francis explain, 
EHRs could also become a catalyst for the role of autonomy in upholding 
consent, privacy, and confidentiality: 
Process-driven, technologically enabled healthcare delivery, of which the EHR 
is a core component, seeks to minimize the role of the individual autonomous 
physician (and the correlative autonomous patient). . . . [T]he adoption of EHR 
technologies should be used as an opportunity to reverse this [instrumental] 
trend and adopt an approach to patient privacy and confidentiality that 
recognizes an autonomy-based, default position of full patient control over 
personal information.100 
Recognition of patient autonomy in the HIT movement is a means by 
which to gain patient trust in electronic record-keeping.101  Trust is crucial in a 
regime vulnerable to security and privacy breaches,102 but autonomy is about 
much more than assuaging security and privacy concerns.103  Indeed, advances 
in HIT are positioned to reduce security concerns, thereby mitigating the need 
for consent as a tool against breach.104  To highlight the per se importance of 
 
 98. See supra notes 82–89 and accompanying text. 
 99. Terry & Francis, supra note 68, at 699–700. 
 100. Id. at 700 (internal citation omitted). 
 101. See Gilman & Cooper, supra note 11, at 315–16; Terry & Francis, supra note 68, at 700. 
 102. Francis, supra note 3, at 37. 
 103. See supra notes 81–87 and accompanying text. 
 104. For example, the ONC has charged the Health IT Policy Committee, through its Privacy 
and Security Tiger Team, to make recommendations regarding privacy and security in a NHIN.  
Supra note 23 and accompanying text. 
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patient autonomy, this Comment presupposes a possible world devoid of 
hackers, of breach.  Even in such a utopia, “informed consent” should be part 
of basic HIE vocabulary.  Put another way, the issue of patient control should 
be approached not from the perspective of defense against illicit access, but 
rather in recognition of the patient’s autonomous nature. 
III.  INFORMED CONSENT TO CLINICAL USE OF EHRS 
The preceding section proposed that the concept of informed consent is 
important—important in relation to privacy rights and more to the point here, 
as a safeguard of autonomy.  This section focuses on the application of 
informed consent.  Granted a role for informed consent in patients becoming 
HIE stakeholders, what consent model best facilitates patients as autonomous 
agents?  Taking up this question, this section proposes that the consent model 
most closely aligned with “autonomous authorization” is one in which patients 
affirmatively opt-in to HIE participation. 
A. In or Out? 
Why “opt-in” rather than “opt-out?”105  Both models give the patient a 
choice in whether to participate and further, the opt-out model would more 
likely ensure higher numbers of EHRs and ease administrative burdens.106  
However, there are benefits to utilizing an opt-in participation model, a model 
requiring affirmative patient action.  First, the risk of breach is pressing in both 
the nascent stages of HIE and as HIE grows nationally.107  “Breach,” defined 
by HHS as “an impermissible use or disclosure under the Privacy Rule [of 
HIPAA] that compromises the security or privacy of the protected health 
information such that the use or disclosure poses a significant risk of financial, 
reputational, or other harm to the affected individual,”108 has become an 
important buzzword in the HIE movement, especially among privacy 
watchdogs.  Consent requirements are unlikely to have much effect on the 
occurrence of breach,109 but the requirements will help to ensure that patients 
are aware of the way(s) in which their information is being used.110  In 
addition, while evidence suggests that the risks of actual harm from breach are 
 
 105. For a detailed consideration of the two options, see MO. OFFICE OF HEALTH INFO. 
TECH., supra note 41, at 42–46. 
 106. See Anderson, supra note 42. 
 107. Terry & Francis, supra note 68, at 724–25. 
 108. Health Information Privacy: Breach Notification Rule, U.S. DEP’T HEALTH & HUMAN 
SERVS. OFF. FOR CIVIL RTS., http://www.hhs.gov/ocr/privacy/hipaa/administrative/breachnotifica 
tionrule/index.html (follow “Definition of Breach” hyperlink) (last visited Mar. 15, 2012). 
 109. Gilman & Cooper, supra note 11, at 327. 
 110. See id. at 284 (explaining that consent and breach notification requirements are unlikely 
to affect incidences of breach, but that most benefits will arise from “the utility that patients 
derive from the fact that they have dominion over their personal medical information”). 
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relatively low,111 the risks will likely increase as information is aggregated to a 
greater degree.112  One response to the problem of breach has been to require 
notification; HITECH mandates that parties affected by breach, including 
patients, be notified of any unauthorized disclosure of protected health 
information.113  However, this response may do more harm than good.  While 
knowing that they will be alerted if their records are illicitly accessed would 
seem to bolster patients’ comfort with HIE, actually receiving notifications 
may undermine patients’ trust in the exchange: “[I]f notifications become 
commonplace, consumers may begin to develop unfounded fears of HIT.”114 
Apart from privacy and security concerns, an opt-in model better facilitates 
and reflects the goal of having autonomous patients as participants in HIE.  
The consent model in place should promote patients’ understanding of (rather 
than mere acquiescence to) the uses of and potential risks to their personal 
health information.115  If a patient must affirmatively manifest her consent to 
being part of HIE, it is more likely that her consent is genuine.116  Thus the 
opt-in model, as opposed to the opt-out, better reflects the goal of the patient as 
an integral stakeholder in HIE.  On a practical note, the opt-in model may ease 
some administrative burdens when sensitive health information is being 
exchanged.  Sensitive health information generally commands additional 
patient privacy and confidentiality protections,117 and an exchange-wide opt-in 
model relieves providers from distinguishing consent models based upon the 
data-type eligible for exchange or the providers slated to access the 
information.118 
 
 111. Id. at 323–24. 
 112. Id. at 321–22 (describing the way in which the aggregation of EHRs may “facilitate 
misuse by reducing the cost of theft” through illicit remote access and easy storage). 
 113. 42 U.S.C. § 17932 (Supp. III 2010). 
 114. Gilman & Cooper, supra note 11, at 331. 
 115. See Tripathi et al., supra note 35, at 438–39. 
 116. MO. OFFICE OF HEALTH INFO. TECH., supra note 41, at 44–45. 
 117. Stephen J. Weiser, Breaking Down the Federal and State Barriers Preventing the 
Implementation of Accurate, Reliable and Cost Effective Electronic Health Records, 19 ANNALS 
HEALTH L. 205, 207–08 (2010); see 42 C.F.R. § 2.31(a)(1) (2010) (describing federal 
requirement of written consent to disclosure of drug and substance abuse information); 45 C.F.R. 
§ 164.508 (2010) (describing federal requirement of authorization for disclosure of psychotherapy 
notes); MO. OFFICE OF HEALTH INFO. TECH., supra note 41, at 44 (chart listing protections 
required for sensitive information by Missouri state law). 
 118. See, e.g., MO. OFFICE OF HEALTH INFO. TECH., supra note 41, at 45 (describing inability 
to exchange sensitive health information in Missouri using an opt-out model); N.Y. EHEALTH 
COLLABORATIVE, PRIVACY AND SECURITY POLICIES AND PROCEDURES FOR RHIOS AND THEIR 
PARTICIPANTS IN NEW YORK STATE – V2.2, at 12 (2011), available at http://nyehealth.org/ 
images/files/File_Repository16/pdf/final%20pps%20v2.2%204.1.11.pdf (outlining New York’s 
affirmative consent approach and explaining that through affirmative consent, authorized parties 
can access all protected health information, including sensitive health information). 
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B. All or Nothing? 
Having granular choices in a consent model will allow patients who might 
not participate under an all-or-nothing approach to consent to some degree of 
participation.  As described in Part I, granular approaches will allow patients to 
opt in or out of participation based upon factors such as data-type, provider, 
data age, or purpose of access.119  This granular approach places the burden of 
communication on the various stakeholders to educate patients on the 
stakeholders’ legitimate purposes for accessing EHRs.120  In this way, the 
granular approach becomes an important mechanism with which other 
stakeholders can garner patient trust and willingness to participate. 
As states consider and implement HIE consent models, granular opting has 
remained at the foot of the table while decisions regarding whether and how to 
gain patient consent (that is, “no consent” versus “opt-in” versus “opt-out’’) 
are resolved.121  Rhode Island is one of the few states to have implemented 
(provider-based) granular opting in its consent model.122  In the Rhode Island 
HIE, currentcare, a patient must explicitly opt in to the exchange and then 
must grant authorization before a stakeholder may access the patient’s 
information through the exchange.123  Further, the information that may be 
accessed by an authorized stakeholder is limited according to the stakeholder’s 
role: for example, a primary care physician has “system permission” to access 
the patient demographics, but may not access the data quality function in the 
exchange, whereas authorized data management specialists may access the 
data quality function.124  The Rhode Island model does not, however, have 
options for patients to limit provider access to patient health information 
according to health information type; that is, a provider may not access system 
management functions, but it has full access to patient health records.125  It 
 
 119. See supra note 48 and accompanying text. 
 120. See Tripathi et al., supra note 35, at 439 (describing this burden in the context of an opt-
in approach). 
 121. See GOLDSTEIN, supra note 7, at 6.  However, the ONC has recently announced a grant 
opportunity for states to focus on and pursue granular consent options.  OFFICE OF THE NAT’L 
COORDINATOR FOR HEALTH INFO. TECH., HEALTH INFORMATION EXCHANGE CHALLENGE 
PROGRAM: FUNDING OPPORTUNITY ANNOUNCEMENT 4–5 (2010). 
 122. GOLDSTEIN, supra note 7, at 15–16. 
 123. R.I. HEALTH INFO. EXCHANGE, RI HIE ENROLLMENT POLICY 1 (2008), available at 
http://www.currentcareri.org/matriarch/documents/Enrollment_Policy_And_Procedure_2008_ 
Apr%2024_FNL_Approved.pdf. 
 124. R.I. HEALTH INFO. EXCH., RI HIE ROLE-BASED PERMISSIONS POLICY 2 (2008), 
available at http://www.currentcareri.org/matriarch/documents/Role-based%20Permissions-
2008_Mar_27-FNL.pdf. 
 125. Id. at 3.  The Rhode Island HIE has attracted attention recently; the American Civil 
Liberties Union filed suit against the Exchange for failing to explicitly address patient privacy, 
confidentiality, and informed consent protections.  Mike Miliard, ACLU Brings Suit Against 
Rhode Island HIE, HEALTHCARE IT NEWS (Sept. 8, 2010), http://www.healthcareitnews.com/ 
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remains unclear whether a granular framework could be viable on a national 
level.  The granular approach highlights the challenges facing those charged 
with the task of standardization: restrictions on data access and transparency 
vary state to state, but if a multi-state or national approach to HIE is to be 
achieved, there must be some standardization of the protection of sensitive 
health information.126  Section C below considers challenges to implementing 
opt-in and/or granularity in the patient participation model. 
C. Challenges of Implementing Robust Consent 
“All too often, considerations of ethical nicety founder on the rocks of 
pragmatic reality.”127  This statement concisely identifies one of the biggest 
problems facing the realization of a robust consent model: is it merely an 
“ethical nicety” to be dispensed of when financial cuts loom?  Is it a platform 
for philosophers and ethicists, but a moot point for patients?  This section 
weighs the costs of a robust HIE patient consent model. 
1. Challenges to “Opt-in” 
The practicalities of implementing an opt-in consent model may be the 
biggest challenge to its adoption.128  During a clinical encounter, a provider 
would furnish a form explaining the uses of EHRs, the stakeholders who would 
access the EHRs, benefits of having an EHR, risks pursuant to the exchange, 
and the ways in which the EHRs would be protected.129  An agreeing patient 
would then affirmatively give her consent to the creation of an EHR.130  
Theoretically, this could be a once-and-done authorization, adjusted only if the 
patient changed her mind (or, in a granular model, her particular preferences) 
 
news/aclu-brings-suit- against-rhode-island-hie.  While the exchange allows patients to consent to 
access based upon provider, it does not create exceptions based upon sensitive health information.  
Id. 
 126. Terry & Francis, supra note 68, at 728. 
 127. Eike-Henner W. Kluge, Informed Consent to the Secondary Use of EHRs: Informatic 
Rights and Their Limitations, in MEDINFO 2004: PROCEEDINGS OF THE 11TH WORLD 
CONFERENCE ON MEDICAL INFORMATICS 635, 637 (Marius Fieschi et al. eds., 2004). 
 128. See Kristen Rosati, Consumer Consent for Health Information Exchange: An 
Exploration of Options for Arizona’s HIEs, ARIZ. HEALTH-E CONNECTION 5–6, 
http://www.azgita.gov/ehealth/hispc/ConsumerConsent.pdf (last visited Mar. 15, 2012) 
(describing administrative burdens of an opt-in approach). 
 129. N.Y. EHEALTH COLLABORATIVE, MODEL LEVEL 1 MULTI-PROVIDER CONSENT FORM 1 
(2011), available at http://www.nyehealth.org/images/files/Policies/level_1_multi-provider_con 
sent_form%20v%202.1.doc [hereinafter MULTI-PROVIDER CONSENT FORM]; see Terry & 
Francis, supra note 68, at 726. 
 130. MULTI-PROVIDER CONSENT FORM 1, supra note 129. 
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about participating.131  Consent during an office or hospital visit could 
encompass consent for the laboratory as well, just as consent for one’s primary 
care physician could encompass consent for referred specialists. 
Despite the sufficiency of a once-and-done authorization, providers may 
decide to seek patients’ consent upon each visit.  First, obtaining HIE consent 
with each visit may be administratively easier because providers could just 
include the opt-in form as a routine aspect of patient treatment.  Second, by 
obtaining consent with each visit, the provider has more assurance that the 
patient still wants to have an EHR.  This is especially relevant in light of the 
legal uncertainty regarding consent and disclosure requirements, which has 
prompted participating providers to over-comply in order to avoid liability.132  
However, if having a patient opt-in involves excessive instances of obtaining 
consent and if there is variation across providers regarding the consent forms 
used, the benefits of the opt-in model may be outweighed by onerous 
implementation challenges: “Rapid and low-cost exchange of health 
information” becomes difficult when consent requirements stand as a barrier to 
information exchange.133 
Further, with a great deal of variation across providers added to an already 
uncertain legal environment, providers may be hesitant or unwilling to share 
information.134  Another problem with defensively giving patients the consent 
form is that a patient might unwittingly decline to consent, perhaps forgetting 
that during the previous visit she had consented.  Of course, if the patient is 
truly giving autonomous authorization rather than just signing her name, she 
will not randomly change her mind about participation.  However, autonomous 
authorization is only a goal and by no means a current reality for all instances 
of informed consent.  The HIE consent process must facilitate autonomous 
authorization while at the same time balancing the importance of generating a 
robust pool of EHRs. 
With the opt-in model, some research shows a potential cost of insufficient 
patient participation,135 stripping from an optimal HIE the benefits of the 
aggregation effect.  Applying a network effect model, the benefits of HIE 
materialize only as more providers (and accordingly more patients) 
 
 131. N.Y. EHEALTH COLLABORATIVE, supra note 118, at 6, 14–15 (describing the durable 
effect of affirmative consent in New York for Level 1 Use—treatment, quality improvement, care 
management, and insurance coverage review); see also GOLDSTEIN, supra note 7, at 20. 
 132. See Tripathi et al., supra note 35, at 438 (describing “[u]ncertainty among legal experts 
about what constitutes consent in an electronic environment” as one reason that the Massachusetts 
eHealth Collaborative (“MAeHC”) implemented the protective opt-in consent model rather than 
an opt-out model). 
 133. Gilman & Cooper, supra note 11, at 327–28. 
 134. Id. at 328. 
 135. GOLDSTEIN, supra note 7, at 52–53. 
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participate.136  However, stringent privacy protections—including robust 
consent models—have been shown to reduce network effects in HIT, with 
states in which robust consent is required showing up to twenty-five percent 
lower HIT adoption rates.137  Still, robust consent—including the opt-in and 
granular models—could also serve to encourage patient participation, engaging 
patients as equal stakeholders in exchange.138  While adoption rates may be 
slower, HIE will be more viable in the long run if patients are truly engaged.139  
In the wise words of the tortoise, “slow and steady wins the race.”  In addition, 
some initiatives project that both opt-in and opt-out consent models would 
garner high participation rates.140 
2. Challenges to Granularity 
Technological barriers are chief among challenges associated with an opt-
in with exceptions consent model.  While a granular approach gives patients 
increased control over their EHRs, it also requires complex software from 
vendors.141  The complex technology required is a major reason why granular 
opting has not been widely adopted or even seriously considered by HIOs, 
intrastate and interstate initiatives, and the ONC.142  Still, stakeholders should 
vigorously encourage vendors in this area so that demand for granularity in 
turn prompts technological developments.143  A concept from the pollution 
context illustrates this point and may serve as a model for developments in 
HIT.  Environmentalist Bruce La Pierre identified three ways in which 
“technology-forcing” may prompt improvements in pollution control: “the 
implementation of an existing technology on a wider basis within an industry, 
the development of a theoretical technology or the transfer of control 
technology between industries, and the development of an entirely new, 
innovative technology or process.”144  As technology develops, the current 
 
 136. Gilman & Cooper, supra note 11, at 310–11. 
 137. Id. at 312. 
 138. Tripathi et al., supra note 35, at 438 (explaining that for the MAeHC, consumer councils 
and advocacy organizations called for patients to be custodians of their medical information). 
 139. Id. at 442. 
 140. MO. OFFICE OF HEALTH INFO. TECH., supra note 41, at 46; Tripathi et al., supra note 35, 
at 441 (showing a ninety percent opt-in rate for the MAeHC). 
 141. See Eramo, supra note 67, at 24, 26 (describing the view of an industry practitioner that 
achievement of granular opting is not viable); Versel, supra note 34. 
 142. See supra note 121 and accompanying text. 
 143. INST. OF MED., CROSSING THE QUALITY CHASM: A NEW HEALTH SYSTEM FOR THE 
21ST CENTURY 5 (2001), available at http://www.iom.edu/~/media/Files/Report%20Files/2001/ 
Crossing-the-Quality-Chasm/Quality%20Chasm%202001%20%20report%20brief.pdf. 
 144. D. Bruce La Pierre, Technology-Forcing and Federal Environmental Protection 
Statutes, 62 IOWA L. REV. 771, 773 (1977). 
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challenges presented by granularity weigh in favor of implementing robust 
consent on a macro level; that is, implementing global opt-in consent.145 
As mentioned in Part I, funding is also a major concern for HIE 
initiatives,146 and a granular approach to patient consent is expensive, requiring 
more complex hardware and software.147  A related issue is that while 
providers bear the brunt of the costs of implementation,148 the benefits are 
predicted to flow equally if not in greater degrees to patients, payers, and 
researchers.149  For providers hesitant to adopt expensive EHR technology,150 
their willingness to adopt granular technology—technology that, as described 
next, has detrimental potential for care—may be slight at best.151 
Cost concerns aside, providers may feel that they have much to lose from a 
granular consent model.  From a provider’s perspective, certain types of 
granular opting may create incomplete patient EHRs or prevent some providers 
from having a full and clear record of a patient’s health.152  This could 
negatively impact quality of care,153 not to mention expose the provider to 
increased risks of liability and difficulties in coordinating care.154  However, 
the trust engendered by robust consent—including granular opting—may 
mitigate the risk of incomplete medical records and low participation; a 
 
 145. Bob Brown, Column, Protecting the Confidentiality of Medical Records in an 
Interconnected Environment, J. HEALTH CARE COMPLIANCE, Nov.–Dec. 2010, at 35, 38. 
 146. See supra notes 30–31 and accompanying text. 
 147. See Joseph Conn, Patient Consent and ‘Granular’ Privacy Control Ties, 
MODERNHEALTHCARE.COM (Dec. 14, 2010, 11:00 AM), http://www.modernhealthcare.com/ 
article/20091214/REG/312149987 (describing stakeholder complaints that granular opting is, 
among other things, expensive, but calling for the health care industry to nonetheless pursue the 
technology). 
 148. Gilman & Cooper, supra note 11, at 299. 
 149. Id. at 281–82. 
 150. See Adam Wright et al., Physician Attitudes Toward Health Information Exchange: 
Results of a Statewide Survey, 17 J. AM. MED. INFORMATICS ASS’N 66, 66 (2010) (reporting the 
results of a 2007 survey where, although a high percentage of responding physicians felt that HIE 
would result in overall benefits to quality of care, costs, and time, only thirty-seven percent would 
be willing to pay $150 or more per month to participate). 
 151. See GOLDSTEIN, supra note 7, at 26–27 (describing the position of the American 
Medical Association and the American College of Physicians—that with the exception of 
sensitive health information, physicians should have “unencumbered” access to all patient 
medical data). 
 152. Id. at 8. 
 153. See Eramo, supra note 67, at 26; Letter from Simon P. Cohn, supra note 52, at 5. 
 154. See Shana Campbell Jones et al., The Interoperable Health Record: Preserving its 
Promise by Recognizing and Limiting Physician Liability, 63 FOOD & DRUG L.J. 75, 82–83 
(2008) (discussing implications of interoperable EHRs on physician liability, including problems 
grounded in a physician’s inability to access a complete EHR).  For a general illustration of the 
potential negative consequences of HIT for patient care, see James McCormack et al., H.I.T. or 
Miss, in TRANSFORMING HEALTH CARE THROUGH INFORMATION: CASE STUDIES 97 (Laura 
Einbinder et al. eds., 3d ed. 2010). 
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patient’s willingness to participate fully may correspond to the degree to which 
the patient is able to exercise her autonomy in doing so.155  In addition, studies 
show that patients who do not trust their providers are more likely to engage in 
risky and evasive behavior that taints medical records.156  As privacy advocate 
Deborah C. Peel explains, “[w]hen patients realize they can’t control who sees 
their electronic health records, they will be far less likely to tell their doctors 
about drinking problems, feelings of depression, sexual problems, or exposure 
to sexually transmitted diseases.”157 
The preceding paragraphs lay out the (at times high) costs of welding 
together HIE and robust patient consent.  These costs may be overwhelming if 
the benefits of robust consent are diminished; that is, if by opting in, a patient 
exercises no more than her ability to sign her name.  This Comment recognizes 
the inherent limitations to the legalized and defensive context in which consent 
is gained by the checking of boxes and initialing what can be highly legalistic 
and complex risk disclosures.158  To be sure, the health care industry has yet to 
fully embrace the late Dr. Jay Katz’s call to escape “the silent world” in which 
doctors and patients too often coexist.159 However, HIT developments are 
happening now.  While implementing a consent model (whether opt-in or opt-
out) is not sufficient for the achievement of patient autonomy in HIE, it is 
certainly necessary.160  It is equally important that implementing an opt-in 
consent model not be the end of the informed consent discussion.  Initiatives to 
educate patients on HIE and patients’ roles through EHRs, along with 
continued conversations between provider and patient, are some of the ways in 
 
 155. See Francis, supra note 3, at 40 (discussing how patients’ trust in their providers may be 
undermined when providers have access the patient did not expect the provider to have). 
 156. McGraw et al., supra note 94, at 417 (explaining that one in six adults report 
withholding information from providers due to fear of inadequate privacy protections). 
 157. Peel, supra note 13, at A17. 
 158. Alan Meisel, From Tragedy to Catastrophe: Lawyers and the Bureaucratization of 
Informed Consent, 6 YALE J. HEALTH POL’Y L. & ETHICS 479, 481 (2006). 
 159. See id. at 481–82 (citing JAY KATZ, THE SILENT WORLD OF DOCTOR AND PATIENT 
(1984)). 
 160. In a recent article addressing patient consent and autonomy generally, philosopher 
Natalie Stoljar points out the insufficiency of informed consent, an “opportunity” concept, to 
secure patient autonomy, an “exercise” concept. Natalie Stoljar, Informed Consent and Relational 
Conceptions of Autonomy, 36 J. MED. & PHIL. 375, 381 (2011).  Merely presenting an 
opportunity for a patient to consent does not ensure that the patient will exercise her choice in 
accordance with conditions of an autonomous choice—what Stoljar describes as “self-referring 
attitudes” such as self-esteem and self-trust.  Id. at 378–79, 381–82.  Further, informed consent 
does not normally require the patient to be what the Stoljar calls a “strong evaluator”—an 
individual who makes qualitative assessments of the values inherent to the choice at hand.  Id. at 
382.  Despite its insufficiency, informed consent should not be whole cloth “jettisoned.”  Id.  
Stojar calls for providers to “encourage imaginative reflection on different options and create the 
conditions in which patients truly feel authorized to speak for themselves.”  Id. at 383. 
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which the consent options exercised by patients may become more 
meaningful.161  Placing the burden of communication on the stakeholder by 
implementing an opt-in model is a good start. 
IV.  CONSENT TO NON-CLINICAL USES OF EHRS 
In the preceding sections, this Comment has explained the goal of 
establishing EHRs for all patients by 2014.  It has also highlighted the concept 
of informed consent as a dynamic feature of patient autonomy and specifically, 
as an important topic for consideration as states and the nation as a whole work 
toward the goal of improving health care through HIE.  This section takes up 
briefly the issue of secondary, non-clinical uses of EHRs.  There are various 
and notable non-clinical purposes that may be served with aggregated health 
information. 
A common feature to all these purposes is that patients derive only indirect 
benefits.162  Those outside the treatment context—including payers, 
researchers, and public health analysts—are focused on benefits that extend 
beyond the well-being of the individual patient, whether it be the insurance 
pool, the bottom line, the future of medicine, or community health.163  
Focusing here on the non-clinical uses of this information by payers, this 
Comment argues that secondary use of EHRs is a game-changer and thus 
requires fresh consideration of patient informed consent.  Section A considers 
the role of payers in HIE and some of the factors that distinguish payers from 
providers as related to the use of EHRs.  These factors highlight the 
importance of informed consent but also reaffirm the importance of an 
approach that combines robust consent and stringent privacy protection.  
Section B then concludes by addressing the feasibility and implications of 
consent for payer inclusion in HIE, including what this consent process looks 
like functionally in relation to the process by which providers obtain consent. 
A. The Payer “Dilemma” 
The role of the payer is only recently becoming a focus in the HIE 
discussion, but it must be considered carefully.  Payer access affects many 
 
 161. See BERG ET AL., supra note 1, at 171 (explaining that through continued 
communication, informed consent can be a process rather than an event); Greenbaum et al., supra 
note 40, at 4-1, 5-4 to -5 (noting the important role of education in engaging patients in HIE, a 
goal for which many state-level education committees have been formed). 
 162. For discussion of patients serving as means rather than ends and deriving only indirect 
benefits in the research context, see Jay Katz, Human Experimentation and Human Rights, 38 ST. 
LOUIS U. L.J. 7, 12–17 (1993), reprinted in CARL H. COLEMAN ET AL., THE ETHICS AND 
REGULATION OF RESEARCH WITH HUMAN SUBJECTS 307–09 (2005). 
 163. See Campbell Jones et al., supra note 154, at 76–77 (describing public health benefits 
that may accrue from interoperable EHRs). 
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aspects of the envisioned goal—from HIE long-term viability, to improved 
care and reduced hospital encounters for patients, to the willingness of patients 
and providers to participate.164  While this Comment addresses payer 
involvement primarily insofar as it has bearing on patient informed consent, it 
is worth describing briefly the relationship between payer participation and 
HIE generally; this macro view illustrates why payers are important to HIE and 
consequently, why the issue of consent must be at the forefront of the 
conversation. 
1. What Payers Bring to the Table 
Current HIE initiatives cite funding and sustainability as top challenges to 
HIE development.165  Achieving a financially and structurally sustainable 
business model is a goal for which payers are slated to be of aid: “Lowering 
the costs of care by reducing duplicate tests and identifying diseases earlier can 
enable payors to invest in strategies that can engender long-term loyalty among 
plan providers and patients.”166  Beyond assuaging cost concerns, the 
aggregated health information databases of payers—largest among HIE 
stakeholders—are a potentially invaluable contribution to the HIE data pool.167  
In addition, payers and employers may be effective in engaging patients to sign 
up to participate in HIE during plan enrollment.168  Accompanying these 
benefits offered by payer participation are benefits to be reaped by the payers 
in participation: payers, like providers, are concerned with health care quality, 
which directly affects their expenditures.169  To this end, some payers have 
been encouraging their members to create payer-based health records to store 
 
 164. Daniel et al., supra note 8, at 830–31. 
 165. EHEALTH INITIATIVE, supra note 16, at 30. 
 166. DELOITTE & TOUCHE USA LLP, supra note 2, at 9; see Jan Walker et al., The Value of 
Health Care Information Exchange and Interoperability, HEALTH AFF., W5-10, W5-15 (Jan. 19, 
2005), http://content.healthaffairs.org/content/early/2005/01/19/hlthaff.w5.10.short (projecting 
savings of around twenty billion dollars for the nation with a highly interoperable system of 
provider-payer transactions). 
 167. Lynne Dunbrack, The Future of Payer-Sponsored Electronic Health Records, 
EXECUTIVE HEALTHCARE, Q4 2008, at 114, 114, available at http://www.executivehm.com/ 
article/The-Future-of-Payer-sponsored-Electronic-Health-Records/ (last visited Mar. 15, 2012); 
Caralyn Davis, Health Information Exchanges: Multiple Benefits, No Downside to Early Payer 
Involvement, FIERCEHEALTHPAYER (Jun. 21, 2010, 8:44 AM), http://www.fiercehealthpay 
er.com/story/health-information-exchanges-multiple-benefits-no-downside-early-payer-involve 
ment/2010-06-21.  But see Joy M. Grossman et al., Information Gap: Can Health Insurers 
Personal Health Records Meet Patients’ and Physicians’ Needs?, 28 HEALTH AFF. 377, 385 
(2009) (“Most physicians had serious concerns about the validity of claims data for treatment 
purposes.”). 
 168. Joseph Goedert, The Payer Role in HIEs, HEALTH DATA MGMT. (June 1, 2009), 
http://www.healthdatamanagement.com/issues/2009_67/-28270-1.html. 
 169. GOLDSTEIN, supra note 7, at 27. 
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members’ information (for example, lab tests, recent diagnoses, medical 
histories).170  Providers can access these records to gain a clearer picture of a 
member’s health without ordering extra tests, etc.171  Access to EHRs would 
open another channel for reduced payer costs.172  There is also likely to be a 
high return on investment for payers, with a net value from HIE participation 
and investment of more than twenty-one billion dollars predicted at one 
point.173 
2. What Payers May Take from the Table 
With great power comes great responsibility, and payers are no exception.  
While they have the potential to catapult HIE success,174 their participation 
should prompt other stakeholders to give pause.  This section identifies three 
ways in which payer access to EHRs is distinguished from provider access. 
(1) Trust.  The ONC Health IT Committee’s Tiger Team on Privacy and 
Security has identified the attainment of patient trust as a key goal during 
continued HIE development.175  Patients often view payers with mistrust due to 
payers’ well-documented reputation as self-interested.176  Giving patients the 
option to choose when and to what degree to incorporate their health records 
into an exchange is one way in which patients maintain control when faced 
with the prospect of their EHRs being accessed by a mistrusted source.177  As 
with patients, providers’ trust is crucial to successful HIE, and “providers 
know that the payers’ bottom line and what’s best for the patient don’t always 
 
 170. Id. 
 171. Dunbrack, supra note 167, at 114–15. 
 172. GOLDSTEIN, supra note 7, at 27. 
 173. Walker et al., supra note 166, at 15.  Despite promised financial return on investment 
(“ROI”), analysts note the high start-up costs of HIE as a disincentive for payer participation, 
explaining that strictly financial ROI may be only a long-term reality.  Laura Kolkman, 
Expanding the HIE Funding Pool by Redefining ROI, HEATHCARE INFO. MGMT. SYS., 
http://www.himss.org/ASP/ContentRedirector.asp?ContentID=68449 (last visited Mar. 15, 2012).  
To secure payer incentive, some encourage a redefining of ROI with a focus beyond the financial 
return.  Id. 
 174. See Davis, supra note 167 (noting that payer participation can aid in reducing medical 
costs and improving outcomes). 
 175. Letter from Paul Tang, supra note 66, at 3. 
 176. See generally Elizabeth A. Pendo, Images of Health Insurance in Popular Film: The 
Dissolving Critique, 37 J. HEALTH L. 267 (2004) (describing the “villainized” portrayals of health 
insurers in three films, Critical Care, The Rainmaker, and John Q, and suggesting that the films 
are exaggerated but nonetheless supported in reality). 
 177. Eramo, supra note 67, at 25 (explaining that according to an online survey, seventy-eight 
percent of those polled felt that physicians should have access to EHRs, while only thirty percent 
felt that insurers should have access). 
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jibe.”178  While payers are positioned to offer huge amounts of patient data, 
providers must be willing to trust the data before it becomes beneficial.179  One 
hope, which would bolster both provider and patient trust in payer data, is that 
[P]rivate payers will follow the lead of the Centers for Medicare & Medicaid 
Services (CMS) . . . in making quality of care a priority, and setting up 
incentives for doctors to make it their priority too. . . . [D]octors and their 
provider brethren may end up learning to trust payers, reaping the fruits of the 
patient data that payers are collecting already.180 
(2) Motive.  While the point on trust above addresses a perhaps unjustified 
perception of payers, actual questionable motives are a legitimate source of 
concern for stakeholders.  Today, payers have huge market control and thus the 
ability to impact both cost of care and treatment decisions.181  As described by 
American Medical Association President Cecil B. Wilson, “[w]hen insurers 
dominate a market, people pay higher health insurance premiums than they 
should, and physicians are pressured to accept unfair contract terms and 
corporate policies, which undermines the physician role as patient 
advocate.”182  Will payers use their access to EHRs in order to more 
scrupulously monitor physicians and further dictate patient treatment to be as 
cheap as possible?183  MedChi, the Maryland State Medical Society 
representing over 22,000 physicians, has expressed the concern that payers will 
manipulate EHRs so that patient treatment is aligned with payers’ interests: 
“The battle over who is in charge of treating the patient is being played out 
through EHRs.”184 
(3) Expansion beyond Treatment Circle.  Related to points (1) and (2) 
above is the reality that payers operate outside of the direct treatment context.  
Patients do not derive a direct benefit from payer access to EHRs; rather, the 
resulting benefits will flow primarily to a payer’s bottom line, the insurance 
 
 178. Don Fluckinger, Merging Payer, Provider Data in EHR Systems, HEALTH IT PULSE 
(June 3, 2010, 8:00 AM), http://searchhealthit.techtarget.com/healthitexchange/healthitpulse/ 
merging-payer-provider-data-in-ehr-systems/. 
 179. See Grossman et al., supra note 167, at 385. 
 180. Fluckinger, supra note 178. 
 181. Press Release, American Med. Ass’n, New AMA Study Finds Lack of Competition 
Among Health Insurers (Feb. 1, 2011), available at http://www.ama-assn.org/ama/pub/news/ 
news/competition-health-insurers.page. 
 182. Id. 
 183. See Reed Abelson, Insurers Test New Cancer Pay Systems, N.Y. TIMES, Oct. 20, 2010, 
at B1 (describing insurers’ efforts to decrease physician dependence on individualized and 
expensive cancer treatment plans). 
 184. Patty Enrado, Maryland Physicians Worry About Payer Influence, EHRWATCH (Nov. 1, 
2010, 12:25 AM), http://www.ehrwatch.com/blog/maryland-physicians-worry-about-payer-in 
fluence. 
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industry, and society.185  Patients will indirectly benefit from payer access, but 
expansion of HIE participation beyond the treatment context is also 
accompanied by special risks to all involved.  As information is aggregated and 
stored electronically, it becomes a sort of attractive nuisance.186  The risk of 
breach, addressed in Part III, is correlated with the number of stakeholders in 
HIE,187 and expanding EHR access to payers brings new opportunities for 
breach.  A corollary to the risk of breach, expansion beyond the treatment 
context, may lead to undesirable but authorized use of EHRs if there are 
insufficient mechanisms in place to control the ways in which non-provider 
“qualified organizations” use the information accessed.  Prior to the ARRA, 
there were troublesome vacuums in HIPAA’s Privacy and Security Rules 
protection as related to health information sharing—notably marketing 
exceptions and the exclusion of de-identified information from HIPAA 
protection.188  HIPAA limits marketing measures using protected health 
information without patients’ authorization,189 but it defines “marketing” so as 
to allow exceptions when marketing for covered entities is for “health care 
operations.”190  De-identified information is excluded from HIPAA 
protection,191 and so HIPAA does not preclude covered entities and non-
covered entities alike from exchanging de-identified health information.192  
This presents a major privacy risk because de-identified information is often 
easily re-identified,193 and if an entity not bound by HIPAA obtains the 
information, that entity is not bound by HIPAA to protect the information.194  
In response to the new HIT terrain that is HIE, there have been calls for new or 
revised privacy protections to cover those areas where HIPAA may be 
inadequate.195  Through the ARRA, HITECH has strengthened HIPAA’s 
 
 185. See supra notes 161–62 and accompanying text. 
 186. See Gilman & Cooper, supra note 11, at 321–23 (comparing the difficulties involved 
with unauthorized access to paper records with that of electronic records, along with the increased 
value of information once aggregated). 
 187. Terry & Francis, supra note 68, at 724; Tripathi et al., supra note 35, at 439. 
 188. See, e.g., McGraw et al., supra note 94, at 419; Weiser, supra note 117 at 207; Deborah 
C. Peel, Presentation to the Texas Public Health Committee, Patient Expectations for HealthIT: 
Control over Health Records Privacy Solutions for HIE (May 11, 2010) (unpublished report), 
available at http://patientprivacyrights.org/wp-content/uploads/2010/05/PH-Committee-May-11-
2010.pdf. 
 189. 42 U.S.C. § 17936(a) (Supp. III 2010); 45 C.F.R. § 164.501 (2010). 
 190. 45 C.F.R. § 164.506(c) (2010). 
 191. 45 C.F.R. § 164.514(a) (2010). 
 192. McGraw et al., supra note 94, at 419. 
 193. Peel, supra note 188. 
 194. McGraw et al., supra note 94, at 419. 
 195. David B. Kendall, Protecting Patient Privacy through Health Record Trusts, 28 HEALTH 
AFF. 444, 444–46 (2009) (calling for the creation of health information trusts controlled by 
patients as an improvement on current federal privacy laws); McGraw et al., supra note 94, at 
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Privacy and Security Rules.196  For example, business associates of covered 
entities are now directly bound by the Rules197 and will be subjected to civil 
monetary penalties for non-compliance,198 and HITECH expands “business 
associates” to include all entities that transmit and routinely access protected 
health information.199  HITECH further limits HIPAA-permitted marketing 
uses of protected health information and, with limited exceptions, requires 
authorization when an entity will receive payment for the marketing use.200  
Finally, covered entities and business associates are now required to not only 
exchange the “minimum necessary” protected health information for business 
purposes, but also to consider whether a partially de-identified “limited data 
set” could accomplish the purposes.201  Still, legal uncertainty regarding the 
new terrain that is the future NHIN, these new provisions, and potential 
loopholes stack the deck in favor of requiring informed consent. 
B. Nuts and Bolts of Consent to Payer Access 
Informed consent has heightened importance when patients will not 
directly benefit from another’s access to and use of patients’ EHRs.  Payers 
illustrate this point.  This Comment concludes here by considering the nuts and 
bolts of obtaining informed consent for payer access to EHRs. 
One possibility for facilitating consent to payer participation is allowing 
payers to piggyback on providers, with both stakeholders obtaining consent via 
a single consent form presented to the patient in a clinical encounter.  The form 
could give patients the option to fully opt in to HIE in which both providers 
and payers will access EHRs.  Alternatively, it could include granular options 
so that patients would consent separately to provider and payer access.  While 
combining both stakeholders in a single form is straightforward, red patient 
flags abound.  Patients will affirmatively manifest their consent for both 
stakeholders, but if they have only one choice—either allow both stakeholders 
access or do not participate—they may feel stuck between a rock and a hard 
place; either ignoring their discomfort with payers or forgoing participation 
altogether.  A granular approach within a single form addresses this difficulty, 
 
420–23 (postulating that privacy and security enhancements, currently lacking under HIPAA, will 
help to engage patients in HIE); Latanya Sweeney, GAO Appointee to the Privacy and Sec. Seat 
of the Fed. HIT Policy Comm., Statement before the 21st Century Healthcare Caucus 
Roundtable: Designing a Trustworthy Nationwide Health Information Network (NHIN) Promises 
Americans Privacy and Utility, Rather than Falsely Choosing Between Privacy or Utility (Apr. 
22, 2010). 
 196. See 42 U.S.C. § 17931 (Supp. III 2010). 
 197. Id. 
 198. Id. § 17939(d)(4). 
 199. Id. § 17938. 
 200. Id. § 17935(d)(1). 
 201. 42 U.S.C. § 17935(b)(1)(A). 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2012] MAKING ROOM FOR PATIENT AUTONOMY 913 
but it does not solve the broader problem.  It blurs the purpose of participation 
for treatment to combine both clinical and non-clinical uses into a single 
consent form.  If a patient is to give autonomous authorization rather than 
merely a signature, the object of the authorization should be clearly delineated 
and contextualized—here, the provider for clinical purposes only.  Further, if a 
patient does not fully grasp that she is consenting to access by both providers 
and payers, she may feel surprised and violated when she discovers that her 
provider granted her payer this access, with a resulting harm to the physician-
patient relationship.202  This is not to say that consent to all secondary uses of 
EHRs should occur outside the clinical context.  For example, it may be 
appropriate to include in a provider’s consent form that the government may 
use data from EHRs for quality improvement, which relates directly to the care 
the patient has received, or for information-based research.203 
The alternative to the single encounter consent, then, is to require payers to 
obtain consent on their own and outside of the clinical context.204  This is 
certainly feasible.  Each year, members re-enroll in an insurance plan, whether 
through their employers or independently.205  Thus, payers have an opportunity 
to obtain member consent without establishing a new and burdensome process.  
In New York, for example, payers seeking authorization to access EHRs must 
obtain consent independently from providers.206  This is true even if payers are 
seeking access only for quality improvement, care management, and insurance 
coverage review purposes, what New York describes as “Level 1 uses.”207  If a 
payer is also seeking access for payment, researching, and marketing purposes, 
it must obtain a further level of consent through a “Level 2 use” consent 
form.208  Level 1 and Level 2 uses cannot be collapsed into a single consent 
form, so a payer seeking access for both quality improvement and payment 
purposes must obtain member consent documented in two separate forms.209 
 
 202. Francis, supra note 3, at 40. 
 203. Id. at 45. 
 204. See, e.g., N.Y. EHEALTH COLLABORATIVE, MODEL LEVEL 1 PAYER CONSENT FORM 
(2011), available at http://www.nyehealth.org/images/files/Policies/level_1_payer_consent_ 
form%20v%202.1.doc [hereinafter LEVEL 1 PAYER CONSENT FORM]. 
 205. See, e.g., GIC Mandates that State Employees Re-enroll in their Health Care Plans, 
MASS. SOC’Y PROFESSORS, http://umassmsp.org/gic_mandates_that_state_employees_re-en 
roll_in_their_health_care_plans_--_failure_to_do_so_will_negatively_affect_your_coverage (last 
visited Mar. 15, 2012). 
 206. Compare LEVEL 1 PAYER CONSENT FORM, supra note 204 (Level 1 form used by 
payers), with MULTI-PROVIDER CONSENT FORM, supra note 129 (Level 1 form used by 
providers). 
 207. N.Y. EHEALTH COLLABORATIVE, supra note 118, at 6. 
 208. N.Y. EHEALTH COLLABORATIVE, MODEL LEVEL 2 PAYER CONSENT FORM FOR 
PAYMENT (2009), available at http://nyehealth.org/images/files/Policies/doc%207c_level_2_ 
payer_consent_form_for_payment.doc. 
 209. N.Y. EHEALTH COLLABORATIVE, supra note 118, at 12. 
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Payers might react adversely to being required to implement robust 
consent.210  Alternatively, this may prove to be no problem at all, with one big 
caveat: member consent to payer access becomes a condition of coverage.211  If 
payer access becomes a condition of member coverage, payers will have near 
full participation because, applying a cost-benefit analysis, members would be 
extremely unlikely to forego coverage.212  And members will be left with no 
meaningful choice at all, which is to say, no ability to preclude payers from 
accessing their EHRs.  The option to get coverage through an alternative payer 
may be diminished as HIE grows on a national level and becomes an integral 
aspect of healthcare in the United States.213  Thus, it seems there is a risk that 
patient consent to payer participation may become a moot point.  One way to 
check payer participation is to place limitations on the uses of HIE for which 
patients may consent.214  In this way, when patients authorize a payer to access 
their EHRs, patients are not consenting to a free-for-all use of their health 
information.  HITECH’s strengthening of HIPAA is a start.  While such 
limitations appease some privacy concerns, however, they facilitate merely the 
legal doctrine of informed consent and do little to carve out a role for 
autonomous authorization.  To carve out this role, policymakers should follow 
the model of New York and preclude payers from making member consent a 
condition of coverage.215 
CONCLUSION 
As HIE initiatives yield to exchange on a national level, the role of 
informed consent must not yield to administrative ease, technological 
expediency, or privacy and confidentiality assurances.  Informed consent has 
an independent and irreplaceable role in carving out a place for patient 
autonomy in healthcare, including HIT.  The success of HIE depends in large 
part on patients participating in the creation of accurate and complete EHRs. 
 
 210. GOLDSTEIN, supra note 7, at 27 (“Ultimately, payers hope to realize the benefits of 
electronic exchange through reductions in their own expenditures.  For these reasons . . . payers 
generally would prefer low-resistance consent models that yield high participation and data 
volume.”). 
 211. New York, which has successfully implemented robust consent requirements for payer 
access to EHRs, see supra notes 203–08 and accompanying text, precludes payers from making 
consent a condition of a member’s health plan enrollment and receipt of benefit.  LEVEL 1 PAYER 
CONSENT FORM, supra note 204; N.Y. EHEALTH COLLABORATIVE, supra note 118, at 12. 
 212. See Terry & Francis, supra note 68, at 726 (describing generally the powerful affect of a 
NHIN on the healthcare industry and noting if a NHIN becomes standard, patient choice may 
“become illusory”). 
 213. See id. 
 214. Id. at 730–35 (discussing legal mechanisms by which EHR use may be limited in order 
to protect patient confidentiality). 
 215. N.Y. EHEALTH COLLABORATIVE, supra note 118, at 12. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2012] MAKING ROOM FOR PATIENT AUTONOMY 915 
Facilitating patient participation through autonomous authorization is an 
important first step in this direction.  Having a patient affirmatively opt in to 
HIE will help to ensure that the patient is meaningfully participating in the 
exchange, aware of uses, risks, and benefits that may result.  Payers should 
independently obtain this consent so as to insulate clinical from non-clinical 
uses of EHRs.  As payers take on this task, the lingering and pressing question 
remains whether this solution is actually a catch twenty-two; that is, whether 
patient participation becomes a condition of coverage such that informed 
consent has no bite.  This question may be a helpful testing ground for whether 
patient autonomy holds water as HIE develops beyond the treatment context—
if payers are able to exercise this control over patients’ EHRs, perhaps patients 
will have been left in the back seat. 
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